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Summary
The decatenation checkpoint normally delays entry into mitosis until chromosomes have been disentangled through the ac-
tion of topoisomerase II.We have found that the decatenation checkpoint is highly inefficient inmouse embryonic stemcells,
mouse neural progenitor cells, and humanCD34+ hematopoietic progenitor cells. Checkpoint efficiency increasedwhen em-
bryonic stem cells were induced to differentiate, which suggests that the deficiency is a feature of the undifferentiated state.
Embryonic stem cells completed cell division in the presence of entangled chromosomes, which resulted in severe aneu-
ploidy in the daughter cells. The decatenation checkpoint deficiency is likely to increase the rates of chromosome aberra-
tions in progenitor cells, stem cells, and cancer stem cells.Introduction
Differentiated cells inmany tissues have a relatively short life span
and are continuously replaced by new cells generated from pro-
genitor cells. In human bonemarrow, for example, approximately
200 billion erythrocytes and 70 billion neutrophilic leukocytes are
produced and released into the bloodstream every day (Gunsilius
et al., 2001). There are extensive similarities between progenitor
cells, stem cells, and cancer cells, including the central role of
Wnt signaling (Reya and Clevers, 2005). This realization has
beenadvancedby thediscovery of cancer stemcells, a newly rec-
ognized subset of tumor cells responsible for tumor progression
(Huntly and Gilliland, 2004; Pardal et al., 2003; Reya et al., 2001).
In some cases, cancer stem cells may arise from non-stem cells
that acquire self-renewal capability; in other cases theymay arise
from stem cells that lose proliferative control.
The decatenation checkpoint (Downes et al., 1994) in G2
phase delays entry into mitosis if the chromosomes have not
been sufficiently decatenated or disentangled by topoisomer-
ase II (topo II), the enzyme required for chromosome decatena-
tion and condensation (Holm et al., 1989; Uemura et al., 1987).
Catenations between sister chromatids result fromDNA replica-
tion and must be resolved to ensure proper chromatid segrega-
tion in mitosis. Nonreplicative catenations, formed incidentally
during interphase, alsomust be resolved to enable chromosome
compaction and segregation (Gimenez-Abian et al., 2000). CellsCANCER CELL : DECEMBER 2005 $ VOL. 8 $ COPYRIGHT ª 2005 ELSEVIEwith an inefficient decatenation checkpoint can complete cell di-
vision in the presence of entangled chromosomes, which results
in aneuploidy in the daughter cells (Gorbsky, 1994; Ishida et al.,
1994). Thus, it is possible that a deficiency in the decatenation
checkpoint could generate the aneuploidy and tetraploidy that
are characteristic of many cancer cells.
The decatenation checkpoint is conserved in the plant and an-
imal kingdoms and has been observed in primary cultured cells,
transformed cells, and immortalized cell lines (Deming et al.,
2001; Downes et al., 1994; Franchitto et al., 2003; Gimenez-
Abian et al., 2002). The checkpoint is deficient in many human
bladder cancer and lung cancer cell lines (Doherty et al., 2003;
Nakagawa et al., 2004) but has not been reported to be deficient
in any normal cell type. The decatenation checkpoint is distinct
from the G2/M DNA damage checkpoint (Downes et al., 1994;
Nakagawa et al., 2004), and its mediators are thought to include
the ATR kinase, Polo-like kinase 1 (Plk1), the BRCA1 tumor sup-
pressor, and the Werner’s syndrome helicase (Deming et al.,
2001, 2002; Franchitto et al., 2003).
Here, we report thatmouse and humanmultipotent progenitor
cells have an inefficient decatenation checkpoint. Checkpoint
efficiency increased when embryonic stem (ES) cells were in-
duced to differentiate, which suggests that the deficiency is
a feature of the undifferentiated state. We observed that the
decatenation checkpoint deficiency can result in severe aneu-
ploidy in progenitor cells.S I G N I F I C A N C E
Recent findings indicate that tumor progressiondepends ona subset of tumor cells called cancer stemcells.Wehavediscoveredacell
cycle deficiency in normal progenitor and stem cells that gives rise to mutations that could contribute to the development of cancer
stem cells. This deficiency in the decatenation checkpoint can result in cell division in the presence of entangled chromosomes and
can increase the rates of chromosomal aberrations. Our results suggest that the deficiency is a feature of the undifferentiated state and
does not require an extant mutation. Chromosome aberrations that arise in progenitor and stem cells as a result of this checkpoint de-
ficiency are likely to contribute to tumorigenesis.R INC. DOI 10.1016/j.ccr.2005.11.004 479
A R T I C L EResults and discussion
The decatenation checkpoint can be studied with bisdioxopi-
perazines such as ICRF-193 (Creighton et al., 1969) that specif-
ically inhibit topo II activity without causing DNA chain breaks
(Downes et al., 1994; Roca et al., 1994; Tanabe et al., 1991).
As shown in Figure 1, we observed pseudomitosis following
treatment with ICRF-193 of mouse ES cells, mouse cortical neu-
ral progenitor cells (NPCs), and human CD34+ hematopoietic
progenitor cells. With regard to the decatenation checkpoint,
the term pseudomitosis (Downes et al., 1994) is used to refer
to spindle formation and kinetochore poleward movement in
the presence of entangled chromosomes, which results in aber-
rant chromosome segregation.
The efficiency of the decatenation checkpoint in various cell
types was measured by the pseudomitotic index, which is de-
fined as the frequency of pseudomitosis in ICRF-193-treated
cells divided by the frequency of mitosis in mock-treated cells.
This ratio is normalized for variation in growth rate among cell
types. A high pseudomitotic index indicates an inefficient deca-
tenation checkpoint because the cells have entered mitosis in
the presence of entangled chromosomes. Cultures of unsyn-
chronized cells were treated for 4 hr with 2 mM ICRF-193 or sol-
vent; colchicine was added at 40 ng/ml to accumulate cells in
mitosis or pseudomitosis. We found a high pseudomitotic index
in the stem and progenitor cells (Figure 2A), indicating an ineffi-
cient decatenation checkpoint in those cells. In contrast, two
non-progenitor cell types, primary mouse embryonic fibroblasts
(MEFs) and human lung fibroblasts (IMR-90) (Nichols et al.,
1977), exhibited a low pseudomitotic index, indicating an effi-
cient decatenation checkpoint as observed in many other mam-
malian cell types (Deming et al., 2001; Downes et al., 1994).
As shown in Figure 2B, similar results were obtained over
a broad range of ICRF-193 concentrations that exceeded the
w7 mMconcentration required to completely inhibit topo II activ-
ity in mammalian cells (Clarke et al., 1993). A normal mitosis was
not observed in any cell type after treatment with 2 mM ICRF-
193, indicating that this was an effective concentration. The
Figure 1. Pseudomitosis in stem and progenitor cells treated with topoisom-
erase II inhibitor
Mouse embryonic stem cells (‘‘mouse ES’’), mouse cortical neural progeni-
tor cells (NPC), and human CD34+ hematopoietic progenitor cells were
treated with 2 mM ICRF-193 or solvent (mock) and 40 ng/ml colchicine.
Metaphase spreads were stained with propidium iodide. A pseudomitosis
was distinguished from interphase cells by its condensed, entangled chro-
mosomes.480observed deficiency was independent of colchicine and inde-
pendent of the length of treatment (data not shown).
We considered the specificity of the observed deficiency by
investigating another G2 phase checkpoint, the DNA damage
checkpoint. To this end we compared the effects of ICRF-193
and etoposide, both of which inhibit topo II activity but by dis-
tinct mechanisms: etoposide causes double-strand breaks
that trigger the G2/M DNA damage checkpoint, but ICRF-193
does not (Downes et al., 1994; Skoufias et al., 2004). When ES
cells were treated with etoposide, a dramatic reduction in the
mitotic index was observed in a dose-dependent manner (Fig-
ure 2C). The sharply contrasting effects of ICRF-193 and etopo-
side indicate that the decatenation checkpoint deficiency in ES
cells represents a specific phenotype, since the DNA damage
checkpoint appears to be intact. There is also a clear distinction
at the physiological level between the effects of ICRF-193 and
etoposide: no significant DNA damage is caused by ICRF-193
in ES cells, otherwise the damage checkpoint would be acti-
vated. Our results are consistent with other reports that distin-
guish the decatenation and DNA damage checkpoints (Downes
et al., 1994; Nakagawa et al., 2004).
Figure 2. Inefficient decatenation checkpoint in stem and progenitor cells
A: Unsynchronized cells were treated for 4 hr with 2 mM ICRF-193 or solvent
(mock) and 40 ng/ml colchicine, and metaphase spreads were prepared.
The pseudomitotic index is the frequency of pseudomitosis in ICRF-193-
treated cells divided by the frequency of mitosis in mock-treated cells, as
described in the text. Stem and progenitor cells were compared to mouse
embryonic fibroblasts (MEF) and human lung fibroblasts (IMR-90). Statistics
indicate the highly significant difference between progenitor versus non-
progenitor cells of the same species. In all panels, error bars represent stan-
dard deviation of the mean.
B: The experiment in A was repeated for mouse ES cells and MEFs treated
with 2 mM, 10 mM, or 50 mM ICRF-193 or solvent.
C: The experiment inAwas repeated for mouse ES cells treated with 0.34 mM,
1.7 mM, or 17 mM etoposide or solvent.CANCER CELL : DECEMBER 2005
A R T I C L EIf the contrasting decatenation checkpoint efficiencies in pro-
genitor cells versus non-progenitor cells reflect differences in
developmental state, then the differentiation of progenitor cells
should be accompanied by increased checkpoint efficiency. To
test this hypothesis, we induced ES cells to differentiate in vitro
and measured the decatenation checkpoint efficiency over the
course of differentiation. In one method of differentiation induc-
tion (Smith, 1991), ES cells were plated at low density (day 0) and
treated with retinoic acid starting on day 1. Immunostaining
against Oct-3/4, a stem cell marker (Rosner et al., 1990; Scholer
et al., 1990), indicated that by day 4 the culture consisted almost
entirely of differentiated cells (Figure 3A). We found that the
pseudomitotic index declined steadily with differentiation (Fig-
ure 3B), indicating an increase in the decatenation checkpoint
efficiency. The pseudomitotic index by definition is corrected
for changes in growth rate; while the frequency of mitosis in
mock-treated cells decreasedwith differentiation, the frequency
of pseudomitosis in ICRF-193-treated cells decreased more
rapidly (Figure 3B, inset), yielding the declining pseudomitotic
index shown in the larger graph.
Similar resultswere obtained by anothermethod of differentia-
tion induction (Strubing et al., 1995) in which embryoid bodies
(EBs) were formed in hanging drops, grown in suspension, and
platedon tissuecultureplastic onday4.Thedecatenationcheck-
point assay was performed on days 0, 5, and 8. As shown in Fig-
ure 3C, thepseudomitotic index on days 5 and8was significantly
lower than that onday 0. Againweobserved that the frequency of
mitosis decreased with differentiation but that the frequency of
pseudomitosis decreased more rapidly (Figure 3C, inset). These
data are consistent with the above results and indicate an in-
crease in decatenation checkpoint efficiency during the differen-
tiation of ES cells. The pseudomitotic index declined to the same
level (w32%) with both methods of differentiation. These results
suggest that the inefficient decatenation checkpoint in multipo-
tent progenitor cells is a feature of the undifferentiated state.
An important inference from the data presented in Figures 2
and 3 and Table 1 is that decatenation checkpoint efficiency
was independent of growth rate. In general, the progenitor cells
grew at a faster rate than the differentiated cells, but there was
no obvious correlation betweenmitotic index and checkpoint ef-
ficiency. The lack of correlation was also evident in the differen-
tiation experiments: cells at three points had similar pseudomi-
totic index (w32%) but a 3-fold range of mitotic index (3.1%,
6.5%, and 9.6%).
We investigated the physiological consequences of the ineffi-
cient decatenation checkpoint in progenitor cells by treating ES
cells with ICRF-193 and performing immunofluorescence with
antibodies to microtubule and kinetochore proteins. We ob-
served that ES cells completed cell division in the presence of
entangled chromosomes, which resulted in severe aneuploidy
in the daughter cells (Figure 4). Microtubule staining revealed
proper spindle formation and the completion of cytokinesis;
however, kinetochore staining revealed unequal segregation of
centromeres, and DNA staining confirmed that the daughter
cells contained vastly disproportionate quantities of DNA. The
completion of pseudomitosis could result in many types of an-
euploidy, including tetraploidy, the gain or loss of only one chro-
mosome or chromosome fragment, and the induction of chro-
mosomal translocations. Inhibition of topo II activity has been
used as a means to drive single chromosome loss in order to
generate new cell lines (Clarke et al., 1998).CANCER CELL : DECEMBER 2005We suggest that entangled chromosomes in pseudomitosis
allow the bypass of the spindle assembly checkpoint. Tension
generated by chromosome entanglements—replicative and
Figure 3. Increased efficiency of the decatenation checkpoint in differenti-
ating cells
A: ES cells were induced to differentiate by plating at 104 cells/cm2 at day
0 and treatment with 1027 M all-trans-retinoic acid starting on day 1. Immu-
nostaining against the stem cell marker Oct-3/4 was performed on day
0 (‘‘ES’’) and day 4 (‘‘Diff.’’).
B: ES cells were induced to differentiate by plating at 104 cells/cm2 at day
0 and treatment with 1027 M all-trans-retinoic acid starting on day 1. The
pseudomitotic index was determined on days 0 (before induction), 2, 3,
and 4. Inset: frequency of pseudomitosis (dashed line) and mitosis (solid
line), the ratio of which is presented in the larger graph. Error bars represent
standard deviation of the mean. Statistics indicate the highly significant dif-
ference between checkpoint efficiency on day 0 and day 4.
C: ES cells were induced to differentiate in embryoid bodies as described in
the Experimental Procedures. The pseudomitotic index was determined on
days 0 (before induction), 5, and 8. Inset: frequency of pseudomitosis
(dashed line) and mitosis (solid line), the ratio of which is presented in the
larger graph. Error bars represent standard deviation of the mean. Statistics
indicate the highly significant difference between checkpoint efficiency on
day 0 and day 8.481
A R T I C L Enonreplicative catenations (Gimenez-Abian et al., 2000; Hirano,
1995)—may imitate the tension resulting from amphitelic attach-
ment, thus bypassing the spindle checkpoint and triggering ana-
phase. This is consistent with the finding in which inhibition of
topo II activity reduced activation of the spindle checkpoint in
cohesin-deficient cells (Vagnarelli et al., 2004). Additional de-
fects might be required for the completion of pseudomitosis in
decatenation checkpoint-deficient cells, but that seems unlikely
since it has been observed in many cell types (Downes et al.,
1994; Gorbsky, 1994; Ishida et al., 1994).
Chromosome gain and loss have been observed during the ex
vivo culture of human andmouse ES cells and could be a conse-
quence of the inefficient decatenation checkpoint. In human ES
cells, trisomy 3, isodicentric X chromosome, the recurrent gain
of chromosomes 12 and 17q, and several additional chromo-
some aberrations have been observed (Draper et al., 2004; In-
zunza et al., 2004; Kim et al., 2005; Maitra et al., 2005). In mouse
ES cells, trisomy 8 is common and significantly reduces the suc-
cess of genetic manipulations (Cervantes et al., 2002; Liu et al.,
1997; Longo et al., 1997). Other aspects specific to the cell cycle
in stem and progenitor cells may become additional sources of
genetic instability during ex vivo culture. Aladjem and col-
leagues first reported on differences in the cell cycle between
progenitor and non-progenitor cells (Aladjem et al., 1998). The
Table 1. Mitotic index of cells in this study
Cell type Mitotic index (%)a
MEF 1.6
Human IMR-90 2.3
Mouse ES 12.4
Mouse NPC 3.1
Human CD34+ (donor A) 9.4
Human CD34+ (donor B) 10.3
aPercentage of the cell population in metaphase after 4 hr colchicine treat-
ment; average of at least three samples.
Figure 4. Aneuploidy in ES cells after challenge to the decatenation check-
point
Mouse ES cells were treated with 2 mM ICRF-193 or solvent (mock) and then
analyzed by immunofluorescence with antibodies against kinetochore pro-
teins (CREST serum) and microtubules (a-tubulin).482ex vivo culture of progenitor cells for therapeutic purposes de-
mands more rounds of cell division than these cells typically un-
dergo in vivo, and this could introduce unpredictable genetic
variation into the cell population.
Mutations in progenitor and stem cells that arise from chro-
mosome breakage and nondisjunction due to the inefficient
decatenation checkpoint could contribute to the development
of cancer stem cells. In the laboratory, certain mutations con-
ferred self-renewal properties to committed hematopoietic pro-
genitor cells and resulted in acute myeloid leukemia in mice
(Cozzio et al., 2003; Huntly et al., 2004). Several clinical condi-
tions, including myelodysplasia, juvenile dyshematopoiesis,
and constitutional trisomy mosaicism, have been attributed to
mutations in progenitor cells that consisted of gain or loss of
chromosomes or chromosome fragments (Heaney and Golde,
1999; Hogge et al., 1987; Parlier et al., 1992; Seghezzi et al.,
1996). Pharmaceutical use of topo II inhibitors such as ICRF-
193, which has been used in the clinic as a cardioprotectant
(Andoh and Ishida, 1998), might enhance the risk of aneuploidy
in progenitor cells and cancer stem cells. Wound healing and
chronic stress, which are correlated with elevated cancer risk
(Hofer et al., 1999), mobilize progenitor cells and might expose
inherent cell cycle deficiencies.
Experimental procedures
Cell culture
Mouse ES cells derived from day 3.5 embryos (129/SvEv and J1 strain back-
grounds) were cultured on gelatinized tissue culture dishes in high-glucose
Dulbecco’smedium (DMEM; Gibco) supplementedwith 15% fetal bovine se-
rum (HyClone), MEM nonessential amino acids (Gibco), 2 mM L-glutamine,
100 IU/ml penicillin, 100 mg/ml streptomycin, 0.12 mM b-mercaptoethanol,
and leukemia inhibitory factor (LIF). NPCs (Ge et al., 2002) were isolated
from day 12 mouse embryos; cultured on dishes coated with 2 mg/ml polyor-
nithine and 15 mg/ml fibronectin in DMEM/F12 with B27 supplement, penicil-
lin, streptomycin, and a daily supplement of 10 ng/ml basic fibroblast growth
factor (Peprotech); and used at passage 1 (6–12 days in vitro). The results
comprise data from independent preparations of NPCs with triplicate sam-
ples in both experiments. MEFs derived from day 13.5–14.5 embryos were
cultured on gelatinized dishes in DMEM with 15% serum, L-glutamine, pen-
icillin, and streptomycin, and used at passage 2. IMR-90 cells (Nichols et al.,
1977) were obtained from ATCC at passage 25, cultured in Eagle’s medium
(ATCC) with 10% serum, penicillin, and streptomycin, and used at passages
28 and 30. CD34+ cells were isolated from peripheral blood of human donors
and cryopreserved by the NHLBI PEGT Facility, Fred Hutchinson Cancer
Research Center, Seattle, WA. CD34+ cells were cultured in suspension in Is-
cove’smedium (Gibco) with 20%BIT 9500 serum substitute (StemCell Tech-
nologies) and 100 ng/ml stem cell factor, 100 ng/ml Flt3 ligand, 10 ng/ml
thrombopoietin, 10 ng/ml IL-6, and 10 ng/ml granulocyte colony stimulating
factor (all from Peprotech). The cells were cultured for 2 days, during which
the cell population approximately doubled, before the experiment.
ES cells were induced to differentiate by two methods. Differentiation
by plating at low density (Smith, 1991) was achieved by plating ES cells at
104 cells/cm2 in themedium described above in the absence of LIF and treat-
ing cells with 1027M all-trans-retinoic acid (Sigma) starting 24 hr after plating.
Differentiation by EBs was based on Strubing (Strubing et al., 1995). EB dif-
ferentiation medium was Iscoves medium (IMDM; Gibco) with 20% fetal bo-
vine serum, MEM nonessential amino acids, 2 mM L-glutamine, 100 IU/ml
penicillin, 100 mg/ml streptomycin, and 400 mM monothioglycerol (Sigma).
Twenty microliter droplets containing w600 ES cells in medium with
1027 M all-trans-retinoic acid (Sigma) were incubated for 2 days on the un-
derside of the lids of bacteriological petri dishes filled with PBS; retinoic
acid was included to increase the efficiency of differentiation. EBs were
then incubated in suspension for 2 days in differentiation mediumwithout ret-
inoic acid. On day 4, the EBs were plated on 12 gelatinized 60 mm tissue cul-
ture dishes. EBs were dissociated thoroughly by pipetting before harvesting.CANCER CELL : DECEMBER 2005
A R T I C L EChromosome preparations
ICRF-193 (MP Biomedical) was dissolved in dimethyl sulfoxide and stored in
aliquots at 220ºC. Unsynchronized cells were treated for 4 hr with 40 ng/ml
colchicine (Sigma) and 2 mM ICRF-193 or solvent, unless otherwise noted.
When necessary, cells were detached with trypsin and dissociated by pipet-
ting. Hypotonic treatment consisted of either 75 mM KCl for 20 min at room
temperature or prewarmed diluted serum (1:6 in water) for 20 min at 37ºC.
Cells were fixed in four changes of freshly mixed methanol:acetic acid (3:1)
and spread on cold wet slides. Slides were stained with propidium iodide,
and cells were counted using the 633 objective of a fluorescence micro-
scope. The number of cells counted per sample ranged from 1200 for cell
types with higher mitotic index to 5000 for cell types with lower mitotic index.
Experiments were performed with triplicate samples. The pseudomitotic in-
dex is the frequency of pseudomitosis in ICRF-193-treated cells divided (nor-
malized) by the frequency of mitosis in mock-treated cells and is expressed
as a percentage. The calculation of standard deviation for pseudomitotic in-
dex accounted for the normalization procedure. Student’s t test modified for
small sample size was used to compare cell types and also accounted for the
normalization.
Immunofluorescence
All solutions were based on phosphate-buffered saline(pH 7.2) with 1.5 mM
MgCl2 and 0.9 mMCaCl2. For Oct-3/4 staining, cells were cultured on gelati-
nized glass coverslips and fixed in 3.7% formaldehyde. Cells were per-
meabilized and blocked in 10% goat serum/0.1% BSA/0.5% Triton X-100;
incubated with anti-Oct-3/4 monoclonal antibody (BD Transduction Labora-
tories) diluted 1:20 in block solution; and incubated with Cy3-conjugated
goat anti-mouse antibodies (Jackson Immunoresearch). Slides were
mounted in Vectashield with DAPI (Vector Laboratories).
For CREST and tubulin costaining, cells were treated with 2 mM ICRF-193
or solvent for 4.5 hr, harvested, centrifuged onto glass slides, and fixed in ab-
solute methanol at220ºC for 8 min. Cells were permeabilized in 0.2% Triton
X-100 (Sigma) for 12 min, washed, and blocked in 5% goat serum/0.2%
Tween 20 (both from Sigma). Cells were incubated with CREST serum (Moroi
et al., 1980) (gift of P. Warburton and W.C. Earnshaw) and anti-a-tubulin
monoclonal antibody (DM1A; Sigma) each diluted 1:1000 in blocking solu-
tion, and thenwith FITC-conjugated donkey anti-human andCy3-conjugated
goat anti-mouse antibodies. DNA was stained with 10 ng/ml Hoechst 33258.
Slides were mounted in n-propyl gallate.
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